Drugs / HGS1025
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01434576 | Dec 2011 → Dec 2012 | ulcerative colitis | Human Genome Sciences Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HGS1025 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01434576 ↗ |
| Action | Inhibit | “Anti-CCR5” NCT01434576 ↗ |
| Modality | Monoclonal antibody | “Human Monoclonal Anti-CCR5 Antibody” NCT01434576 ↗ |
| Route | Intravenous | “administered by IV infusion” NCT01434576 ↗ |
| Target | CCR5 | “Anti-CCR5” NCT01434576 ↗ |